187 related articles for article (PubMed ID: 19929434)
1. Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment.
Moore AE; Blake GM; Taylor KA; Rana AE; Wong M; Chen P; Fogelman I
J Bone Miner Res; 2010 May; 25(5):960-7. PubMed ID: 19929434
[TBL] [Abstract][Full Text] [Related]
2. Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis.
Moore AE; Blake GM; Taylor KA; Ruff VA; Rana AE; Wan X; Fogelman I
Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):326-36. PubMed ID: 22057627
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide studies of bone metabolism: do bone uptake and bone plasma clearance provide equivalent measurements of bone turnover?
Blake GM; Siddique M; Frost ML; Moore AE; Fogelman I
Bone; 2011 Sep; 49(3):537-42. PubMed ID: 21689803
[TBL] [Abstract][Full Text] [Related]
4. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling.
Moore AE; Blake GM; Fogelman I
J Nucl Med; 2008 Mar; 49(3):375-82. PubMed ID: 18287266
[TBL] [Abstract][Full Text] [Related]
5. Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearance.
Moore AE; Blake GM; Fogelman I
J Nucl Med; 2006 Apr; 47(4):581-6. PubMed ID: 16595490
[TBL] [Abstract][Full Text] [Related]
6. Quantitative studies of bone in postmenopausal women using (18)F-fluoride and (99m)Tc-methylene diphosphonate.
Blake GM; Park-Holohan SJ; Fogelman I
J Nucl Med; 2002 Mar; 43(3):338-45. PubMed ID: 11884493
[TBL] [Abstract][Full Text] [Related]
7. Quantitative studies of bone using (99m)Tc-methylene diphosphonate skeletal plasma clearance.
Blake GM; Moore AE; Fogelman I
Semin Nucl Med; 2009 Nov; 39(6):369-79. PubMed ID: 19801217
[TBL] [Abstract][Full Text] [Related]
8. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
9. The assessment of regional skeletal metabolism: studies of osteoporosis treatments using quantitative radionuclide imaging.
Blake GM; Frost ML; Moore AE; Siddique M; Fogelman I
J Clin Densitom; 2011; 14(3):263-71. PubMed ID: 21600822
[TBL] [Abstract][Full Text] [Related]
10. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
11. Age-related change of technetium-99m-HMDP distribution in the skeleton.
Kigami Y; Yamamoto I; Ohnishi H; Miura H; Ohnaka Y; Ota T; Yuu I; Masuda K; Morita R
J Nucl Med; 1996 May; 37(5):815-8. PubMed ID: 8965151
[TBL] [Abstract][Full Text] [Related]
12. Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw.
Ohbayashi Y; Miyake M; Sawai F; Minami Y; Iwasaki A; Matsui Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Apr; 115(4):e31-7. PubMed ID: 23246226
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography.
Frost ML; Siddique M; Blake GM; Moore AE; Schleyer PJ; Dunn JT; Somer EJ; Marsden PK; Eastell R; Fogelman I
J Bone Miner Res; 2011 May; 26(5):1002-11. PubMed ID: 21542003
[TBL] [Abstract][Full Text] [Related]
14. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
Dobnig H; Sipos A; Jiang Y; Fahrleitner-Pammer A; Ste-Marie LG; Gallagher JC; Pavo I; Wang J; Eriksen EF
J Clin Endocrinol Metab; 2005 Jul; 90(7):3970-7. PubMed ID: 15840739
[TBL] [Abstract][Full Text] [Related]
15. Quantitative studies of bone using (18)F-fluoride and (99m)Tc-methylene diphosphonate: evaluation of renal and whole-blood kinetics.
Park-Holohan SJ; Blake GM; Fogelman I
Nucl Med Commun; 2001 Sep; 22(9):1037-44. PubMed ID: 11505214
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
17. Validation of ultrafiltration as a method of measuring free 99mTc-MDP.
Moore AE; Hain SF; Blake GM; Fogelman I
J Nucl Med; 2003 Jun; 44(6):891-7. PubMed ID: 12791815
[TBL] [Abstract][Full Text] [Related]
18. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
[TBL] [Abstract][Full Text] [Related]
19. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography.
Frost ML; Cook GJ; Blake GM; Marsden PK; Benatar NA; Fogelman I
J Bone Miner Res; 2003 Dec; 18(12):2215-22. PubMed ID: 14672357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
